Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ATLCAR.CD138 |
| Trade Name | |
| Synonyms | CART-138|CD138.CAR |
| Drug Descriptions |
ATLCAR.CD138 are autologous T-lymphocytes that are engineered to express a chimeric antigen receptor that targets CD138, potentially resulting in an immune response against CD138-expressing tumor cells and leading to an antitumor response (PMID: 31040928). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ATLCAR.CD138 | ATLCAR.CD138 | 0 | 0 |
| ATLCAR.CD138 + Cyclophosphamide + Fludarabine | ATLCAR.CD138 Cyclophosphamide Fludarabine | 0 | 1 |